Insulin treatment increased the incidence of hypoglycemia in patients with COVID-19 and type 2 diabetes mellitus (T2DM) (14), which may impair the glucose homeostasis and glucose control to affect the COVID-19 outcomes. The gene discussed is INS; the disease is Hypoglycemia.